Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Receives $4.75 Consensus Price Target from Analysts

Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) have earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $4.75.

ADIL has been the topic of a number of research reports. Maxim Group upgraded shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Saturday, September 27th. Wall Street Zen raised Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. Finally, Zacks Research lowered Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Adial Pharmaceuticals stock. Citadel Advisors LLC boosted its holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 63.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 54,508 shares of the company’s stock after buying an additional 21,238 shares during the period. Citadel Advisors LLC owned approximately 0.85% of Adial Pharmaceuticals worth $55,000 as of its most recent SEC filing. 16.41% of the stock is owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Stock Performance

Adial Pharmaceuticals stock opened at $0.39 on Friday. The business’s fifty day moving average is $0.38 and its two-hundred day moving average is $0.50. The firm has a market cap of $8.50 million, a P/E ratio of -0.37 and a beta of 1.36. Adial Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.30.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. On average, equities research analysts predict that Adial Pharmaceuticals will post -1.53 earnings per share for the current year.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.